Login to Your Account

Regulatory NEWS
The 21st Century Cures Act may eventually set a new legislative land speed record for conception to passage in the House of Representatives, but the bill nonetheless reintroduces interested parties to an issue as old as budgets themselves.

"Excited about getting some more alignment and taking some unknowns out of the equation" as it pertains to the path market-ward, CEO Nick Leschly said Bluebird Bio Inc. will consider bringing on a partner to help with Lentiglobin BB305 for beta-thalassemia major.

As the race heats up to translate promising human gene-editing technologies from the academic lab to human trials, U.S. policy advisers are trying to catch up with the research.

More Regulatory Headlines

Cast Your Vote

Has biotech’s bubble burst?: